Rules-Based Medicine (RBM) is a spinout of Luminex Corporation, Austin, Texas. Founded in 1998 as a research and development project within Luminex, RBM developed the first highly multiplexed immunoassay panels. Since RBM’s official inception in 2002 the company has continued to expand their service and product offerings centering on their unique perspective as developers of xMAP Technology. Today, RBM offers the most comprehensive multiplexed immunoassay services to the pharmaceutical, medical research and consumer products industries… RBM employs over 100 people at three facilities: Austin, TX: Corporate headquarters and CLIA-certified biomarker testing laboratory Lake Placid, NY: Multiplex assay development and GMP kit manufacturing Reutlingen, Germany: TruCulture™ and other HOT cell culture services

www.rbmmaps.com

Products and Services:

Rules-Based Medicine (RBM) provides comprehensive protein biomarker products and services centered on its Multi-Analyte Profiling (MAP) technology. Its service platform (RodentMAP® and HumanMAP®) provides pre-clinical and clinical researchers with reproducible, quantitative, multiplexed immunoassay data for hundreds or proteins cost-effectively in multiple species, and from a small sample volume. The testing service supports numerous GLP studies and is CLIA certified. Many of these assays are available as optimized kits through our distribution partner EMD Biosciences. The company also offers innovative and proprietary ex vivo testing systems such as TruCulture™, the first fully-closed, reproducible whole blood culture system. It is available with MAP testing service that provides an unprecedented view of the impact of a drug compound or consumer product on an individual’s immune system without endangering a human test subject. RBM is actively developing multiplex diagnostic tests to detect the presence of complex disease and conditions in areas of unmet medical need such as neuropsychiatry, nephrology immunology and cardiology.